Date: 2012-05-23
Type of information: Capital increase
Company: Thrombogenics (Belgium)
Investors: employees
Amount: €1.383.132,05
Funding type: capital increase from employee warrant exercises
Planned used:
Others: ThromboGenic, a biopharmaceutical company focused on developing innovative ophthalmic medicines, has announced a capital increase arising from employee warrant exercises. Since its inception in 2006, ThromboGenics has used warrant plans to incentivize personnel and management and have them share in the success of the company. Following warrant exercises during the exercise period in May 2012, ThromboGenics issued 121.917 new ordinary shares on 21 May 2012 for a total capital increase (including issuance premium) of €1.383.132,05.
To date, ThromboGenics total share capital amounts to €161.140.106,37; the total number of securities conferring voting rights is 35.813.349 which is also the total number of voting rights (the \"denominator\"). All voting rights are of the same category.
Therapeutic area: Ophtalmological diseases
